BHC Bausch Health
- 6.770
- -0.300-4.24%
- 6.830
- +0.060+0.89%
Bausch Health News
Salix to Present Late-Breaking Data From Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
LAVAL, Quebec, May 17, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phas
RBC Notes Updates on Bausch Xifaxan Patent Litigation With Norwich
Bausch Health announced updates in the Xifaxan patent litigation with Norwich, noting that both parties have filed petitions for panel rehearing or rehearing en banc in the Appellate Court. BHC expect
Bausch Health Shareholders Approve Key Proposals
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
LAVAL, Quebec, May 15, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the results of its 2024 annual meeting of shareholders.Annual Meeting ResultsThe 10 directors nominated at the
Bausch Health Defends XIFAXAN Patents Amid Litigation
Bausch Health: Norwich Seeks to Market Generic Version of Xifaxan 550 Mg Tablets to Treat Irritable Bowel Syndrome With Diarrhea in Adults >BHC
Bausch Health: Norwich Seeks to Market Generic Version of Xifaxan 550 Mg Tablets to Treat Irritable Bowel Syndrome With Diarrhea in Adults >BHC
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters
04:34 PM EDT, 05/14/2024 (MT Newswires) -- Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters
Bausch Health Expects Decision on Rehearing Within Next Three Mos >BHC
Bausch Health Expects Decision on Rehearing Within Next Three Mos >BHC
Bausch Health Seeks Rehearing in Norwich Pharmaceuticals Litigation >BHC
Bausch Health Seeks Rehearing in Norwich Pharmaceuticals Litigation >BHC
RBC Noes Bausch Health Filing For Rehearing in Appellate Court
On Friday evening, Bausch Health filed a petition for rehearing in the Appellate Court in the Xifaxan patent litigation between BHC and Norwich, writes RBC. On April 11, the Appellate Court made a rul
Salix Pharmaceuticals Announces Bellamy Young as Spokesperson for Xifaxan(R) (Rifaximin)
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic Encephalopathy is caused by cirrhosis of the liverAs complications from chronic
Salix Pharmaceuticals Announces Bellamy Young as Spokesperson for Xifaxan
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan (rifaximin)Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt H
Morgan Stanley Upgrades Bausch + Lomb, Cites Improving Margins
Bausch Health Companies (NYSE:BHC Investor Three-year Losses Grow to 72% as the Stock Sheds US$388m This Past Week
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform
Bausch Health reported Q1 EBITDA that was weaker than expected and also provided little incremental visibility on the Bausch + Lomb separation beyond the former noting that the Norwich court decision
Truist Financial Reaffirms Their Hold Rating on Bausch Health Companies (BHC)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Why Bausch Health Companies Stock Dived by More Than 7% Today
Why Bausch Health Companies Shares Are Falling After Q1 Results
Bausch Health Companies Inc. (NYSE:BHC) shares are trading lower on Thursday after reporting first-quarter results.The company reported adjusted quarterly earnings per share of 59 cents, missing the s
Bausch Health Companies Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Revenue Results.
Bausch Health Companies Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Revenue Results.
Analysis
Price Target
No Data
